A research team from i3S/Ipatimup found that the analysis of the stem cell marker P-cadherin in metastasized lymph nodes of breast cancer allows for a better stratification of the overall survival and disease free survival of patients. Specifically, P-cadherin was more effective in this stratification than the classical stem cell markers CD44 and Cd49f, being the gain of P-cadherin in metastasized lymph nodes (vs. primary tumor) is associated with more aggressive disease.
